Xarelto And Pradaxa Stumble At High U.K. Reimbursement Hurdles

NICE issues draft rejection of Bayer's blood thinner Xarelto for use in preventing stroke associated with atrial fibrillation, while a U.K. payer fights a positive recommendation for Boehringer Ingelheim's Pradaxa in the same indication.